In Module 3, APPs will learn key discussion points on responding to patient questions on Biosimilars being effective as their originator Biologics? This module includes techniques on addressing difficult questions of efficiency, safety, and the approval process, again ensuring health literacy and supporting patients in finding additional resources to support them (education, financial, IBD Help Center, etc.).
Module Resource Links:
FDA website on biosimilars with patient and provider information, in English and in Spanish:
https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
FDA Purple Book database: All FDA approved biologic products, including licensed biosimilar and interchangeable products, and their reference products https://purplebooksearch.fda.gov
Crohn’s & Colitis Foundation Website:
- Crohn’s & Colitis Foundation: Biosimilars: What You Should Know: https://www.crohnscolitisfoundation.org/what-is-ibd/medication/biosimilars
- Crohn’s & Colitis Foundation: Medication Guide https://www.crohnscolitisfoundation.org/ibdmedicationguide
- Crohn’s & Colitis Foundation: Biosimilars Role in IBD Treatment https://www.crohnscolitisfoundation.org/blog/biosimilars-role-ibd-treatment
Speakers:
Jamie T. Brogan, APRN
Northwestern Medicine, Digestive Health Center
Chicago, IL
Angelina Collins, MSN, ANP-BC, Board Certified Adult Nurse Practitioner
Inflammatory Bowel Disease Center, UC San Diego Health
La Jolla, CA
Date: 9/1/2023
This program made possible in part by:
